An interventional study of MRI and Biocollection in Myocardial Infarction, sponsored by Hospices Civils de Lyon. Recruiting at 2 sites in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-14.
Sponsored by Hospices Civils de Lyon · Not applicable, Interventional, and Diagnostic
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 49 studies in ST Elevation Myocardial Infarction with a site in France — 7 open to participants now, 11 under way, 5 of them phase 3. ST Elevation Myocardial Infarction · France.
Among the 49 studies in ST Elevation Myocardial Infarction with a site in France, this one is the 25th largest by planned enrollment of the 40 interventional ones that give a count, is one of 4 that started in 2023, is one of 17 with no phase, reaches primary completion later than 10 of the 10 other live ones, and was the 43rd registered.
855 studies on the registry are indexed under ST Elevation Myocardial Infarction; 201 are open to participants now.
Browse ST Elevation Myocardial Infarction studies →7 of the 49 studies in ST Elevation Myocardial Infarction with a site in France are open now. Recruiting first, the newest first:
Poitiers University Hospital · Sites in France
Ages 18+
Assistance Publique - Hôpitaux de Paris · Sites in France
Ages 18+
Assistance Publique - Hôpitaux de Paris · Sites in France
Ages 18+
Assistance Publique - Hôpitaux de Paris · Sites in France
Ages 18+
Club Régional des Angioplasticiens de la région Centre · Sites in France
Ages 18+
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 124 ST Elevation Myocardial Infarction studies recruiting now, 78 (63%) set no upper age limit and 20 (16%) stop at 75 or younger; 10 take children under 18; 9 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
49 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 3 · Phase 3 18 · Phase 4 2
First in 2006; this study’s year is marked. 4 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 300 is above the median of 194 across 531 interventional studies indexed under ST Elevation Myocardial Infarction.
Median enrollment 325 across the 40 interventional studies, 1,027 across the 9 observational. Of the 34 that completed or were terminated, 6 (18%) have results posted.
This tab as a report to print or save as PDF → With an account.
19 of 49 have an industry lead sponsor. The 10 most frequent:
Hospices Civils de Lyon is the lead sponsor of 1,868 studies on the registry; 447 are open to participants now.
Hospices Civils de Lyon has 6 studies filed under ST Elevation Myocardial Infarction — fewer than ten, so there is no comparison to draw.
2 of the studies in ST Elevation Myocardial Infarction with a site in France that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07102628Phase 3Novartis PharmaceuticalsEvaluation of Efficacy and Safety of Early in Hospital Initiation of Inclisiran Treatment in Patients With Acute Coronary Syndromes | 2027-01-16 |
| NCT05211401Assistance Publique - Hôpitaux de ParisRituximab in Patients With ST-elevation Myocardial Infarction | 2027-11 |
Add all 2 to your calendar (.ics) → With an account.
Among the 49 studies in ST Elevation Myocardial Infarction with a site in France, from their registry updates:
This tab as a report to print or save as PDF → With an account.
ST-segment elevation myocardial infarction (STEMI) is an acute condition that accounts for 75% of sudden deaths in adults over 35 years of age and more than half of all cases of chronic heart failure. However, the mechanism of myocardial infarction remains poorly understood. At present, there is no national information system for myocardial infarction, as there is for other diseases such as multiple sclerosis (OFSEP cohort).
The purpose of this cohort is to enable studies and research projects to be carried out on the descriptive epidemiology of myocardial infarction, monitoring of patients undergoing treatment (safety, efficacy), quality of life and functional consequences of infarction, and research into new biological and imaging prognostic biomarkers. Its general objective is to provide researchers, hospital practitioners, medical interns, academics or industrialists with a quality epidemiological tool for research.
855 studies on the registry are indexed under ST Elevation Myocardial Infarction; 201 are open to participants now.
This study's planned enrollment of 300 is above the median of 194 across 531 interventional studies indexed under ST Elevation Myocardial Infarction.
Browse ST Elevation Myocardial Infarction studies →Hospices Civils de Lyon is the lead sponsor of 1,868 studies on the registry; 447 are open to participants now.
Compared within ST Elevation Myocardial Infarction, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Myocardial Infarction. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
patient with ST-segment elevation myocardial infarction.
Other: MRI · Biological: Biocollection · Behavioral: Quality of life questionaries
1 MRI at 1 month with gadolinium injection
Biocollection from blood (H0, H4, H24, H48, 1 month, 1 year), urine (H48) and faecal (initial hospitalisation) samples.
EQ-5D-5L and HAD questionaries at 1 month and 1 year.
Research of potential new markers
Biomarkers assays (prognosis and diagnosis) between inclusion and one-year follow-up (H0, H4, H24, H48, M1, M12 since emergency revascularisation)
Time frame: 1 year
Calculation of infarct size on MRI
Measurement of reperfusion lesions on MRI (mass in grams)
Time frame: 1 month
Pharmacoepidemiology of myocardial infarction.
Description and evolution of patients' medical treatment between hospital discharge and 5 years follow-up.
Time frame: 5 years
Events between inclusion and 5 years follow-up
Time to a major adverse cardiovascular event
Time frame: 5 years
Plan to share: No
Started May 2023 (actual). Primary completion is estimated for Jun 2033, 121 months after the start.
Of 135 non-industry interventional studies with no phase under ST Elevation Myocardial Infarction, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 70. This study's planned 121 months is above that.
Counting every sponsor, half of 145 studies reached it within 40 months; a quarter within 19 and three quarters within 64.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
ST Elevation Myocardial Infarction →